Loading...
XNYS
LLY
Market cap1.13tUSD
Jul 24, Last price  
1,196.03USD
1D
0.86%
1Q
35.30%
Jan 2017
1,526.15%
Name

Eli Lilly and Co

Chart & performance

D1W1MN
XNYS:LLY chart
P/E
54.58
P/S
17.28
EPS
21.92
Div yield, %
0.50%
Shrs. gr., 5y
-1.26%
Rev. gr., 5y
21.58%
Revenues
65.18b
+44.70%
15,691,000,00018,633,500,00020,371,900,00021,836,000,00023,076,000,00024,286,500,00022,603,400,00023,113,100,00019,615,600,00019,958,700,00021,222,100,00019,973,800,00021,493,300,00022,319,500,00024,539,800,00028,318,400,00028,541,400,00034,124,100,00045,042,700,00065,179,000,000
Net income
20.64b
+94.88%
2,662,700,0002,953,000,000-2,071,900,0004,328,800,0005,069,500,0004,347,700,0004,088,600,0004,684,800,0002,390,500,0002,408,400,0002,737,600,000-204,100,0003,232,000,0008,318,400,0006,193,700,0005,581,700,0006,244,800,0005,240,400,00010,590,000,00020,638,300,000
CFO
16.81b
+90.67%
3,975,900,0005,154,500,0007,295,600,0004,335,500,0006,856,800,0007,234,500,0005,304,800,0005,735,000,0004,458,400,0002,964,600,0004,851,000,0005,615,600,0005,524,500,0004,836,600,0006,499,600,0007,365,900,0007,585,700,0004,240,100,0008,817,900,00016,813,000,000
Dividend
Aug 14, 20261.73 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Eli Lilly and Company is a global pharmaceutical enterprise engaged in the discovery, development, and commercialization of human pharmaceutical products. Its diverse portfolio provides treatments across multiple therapeutic areas. In the field of diabetes care, the company offers a comprehensive range of insulins, such as Basaglar, various formulations of Humalog (including U-100, U-200, Mix 75/25, and Mix 50/50), insulin lispro, insulin lispro protamine, and insulin lispro mix 75/25. Additionally, its Humulin line features Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. For the management of type 2 diabetes, key medications include Jardiance, Trajenta, and Trulicity. Its oncology division features medications like Alimta, utilized for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. Cyramza is indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma. Erbitux addresses colorectal cancers and various head and neck cancers, while Retevmo is prescribed for metastatic NSCLC, medullary thyroid cancer, and other thyroid cancers. Tyvyt provides treatment for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC, and Verzenio supports patients with HR+, HER2- metastatic breast cancer, node-positive breast cancer, and early breast cancer. Within immunology, Eli Lilly offers Olumiant for rheumatoid arthritis. Taltz is available as a treatment option for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. For neurological and pain management needs, the company provides Cymbalta, used for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality serves as a preventive measure for migraines and treats episodic cluster headaches. Zyprexa is prescribed for schizophrenia, bipolar I disorder, and bipolar maintenance. Beyond these core areas, Eli Lilly's product line also encompasses Bamlanivimab, etesevimab, and Bebtelovimab for COVID-19; Cialis for addressing erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company maintains strategic collaborations with numerous partners, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc. Founded in 1876, Eli Lilly and Company's corporate headquarters are situated in Indianapolis, Indiana.
IPO date
Jul 09, 1970
Employees
39,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT